JP2014520807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520807A5 JP2014520807A5 JP2014519091A JP2014519091A JP2014520807A5 JP 2014520807 A5 JP2014520807 A5 JP 2014520807A5 JP 2014519091 A JP2014519091 A JP 2014519091A JP 2014519091 A JP2014519091 A JP 2014519091A JP 2014520807 A5 JP2014520807 A5 JP 2014520807A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- polypeptide
- epitope
- composition
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 164
- 102000036639 antigens Human genes 0.000 claims description 164
- 108091007433 antigens Proteins 0.000 claims description 164
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 110
- 229920001184 polypeptide Polymers 0.000 claims description 98
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 97
- 230000002163 immunogen Effects 0.000 claims description 41
- 244000052769 pathogen Species 0.000 claims description 27
- 230000001717 pathogenic effect Effects 0.000 claims description 27
- 230000037452 priming Effects 0.000 claims description 26
- 230000003612 virological effect Effects 0.000 claims description 22
- 241000701022 Cytomegalovirus Species 0.000 claims description 18
- 125000002091 cationic group Chemical group 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 14
- 239000007908 nanoemulsion Substances 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 12
- 239000002502 liposome Substances 0.000 claims description 12
- 239000011859 microparticle Substances 0.000 claims description 12
- 239000004005 microsphere Substances 0.000 claims description 12
- 239000002077 nanosphere Substances 0.000 claims description 12
- 239000000277 virosome Substances 0.000 claims description 12
- -1 Cationic lipid Chemical class 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 239000007764 o/w emulsion Substances 0.000 claims description 10
- 239000007762 w/o emulsion Substances 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 7
- 241000710929 Alphavirus Species 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 15
- 229940127557 pharmaceutical product Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 4
- 239000002356 single layer Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940126601 medicinal product Drugs 0.000 claims 2
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 28
- 239000000839 emulsion Substances 0.000 description 4
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505105P | 2011-07-06 | 2011-07-06 | |
| US61/505,105 | 2011-07-06 | ||
| PCT/US2012/045854 WO2013006842A2 (en) | 2011-07-06 | 2012-07-06 | Immunogenic compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016210783A Division JP2017025103A (ja) | 2011-07-06 | 2016-10-27 | 免疫原性組成物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014520807A JP2014520807A (ja) | 2014-08-25 |
| JP2014520807A5 true JP2014520807A5 (cg-RX-API-DMAC7.html) | 2015-08-20 |
Family
ID=46513884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519091A Pending JP2014520807A (ja) | 2011-07-06 | 2012-07-06 | 免疫原性組成物およびその使用 |
| JP2016210783A Pending JP2017025103A (ja) | 2011-07-06 | 2016-10-27 | 免疫原性組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016210783A Pending JP2017025103A (ja) | 2011-07-06 | 2016-10-27 | 免疫原性組成物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11058762B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2729168A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2014520807A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2841047A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013006842A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3067064B1 (en) | 2008-12-09 | 2020-05-13 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
| SI3243526T1 (sl) | 2010-07-06 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Dostava RNA za sprožitev večih imunskih poti |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| SI3970742T1 (sl) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Pegilirani liposomi za dostavo RNA, ki kodira imunogen |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| BR112013008700B8 (pt) | 2010-10-11 | 2022-10-04 | Novartis Ag | Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| LT2717893T (lt) | 2011-06-08 | 2019-08-12 | Translate Bio, Inc. | Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai |
| US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| BR112014008694A2 (pt) * | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
| US9040397B2 (en) * | 2011-10-21 | 2015-05-26 | LGS Innovations LLC | Method of making graphene layers, and articles made thereby |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| CN104853770A (zh) * | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 免疫原性组合物及其应用 |
| GB2513768B (en) * | 2012-07-06 | 2015-04-15 | Novartis Ag | Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins |
| EP2885419A4 (en) | 2012-08-14 | 2016-05-25 | Moderna Therapeutics Inc | ENZYMES AND POLYMERASES FOR RNA SYNTHESIS |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| CN104902925A (zh) * | 2013-01-10 | 2015-09-09 | 诺华股份有限公司 | 流感病毒免疫原性组合物及其应用 |
| WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| RS66380B1 (sr) | 2014-04-23 | 2025-02-28 | Modernatx Inc | Vakcine nukleinske kiseline |
| PE20170301A1 (es) * | 2014-05-08 | 2017-03-30 | Pfizer | Medios y metodos para el tratamiento cmv |
| MX384992B (es) * | 2014-06-13 | 2025-03-14 | Glaxosmithkline Biologicals Sa | Combinaciones inmunógenas. |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
| BE1024420B1 (fr) * | 2015-06-12 | 2018-02-19 | Glaxosmithkline Biologicals Sa | Polynucleotides et polypeptides d'adenovirus |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| AU2016315478B2 (en) | 2015-09-03 | 2023-07-13 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| ES2810701T5 (es) | 2015-10-05 | 2024-07-11 | Modernatx Inc | Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
| TN2018000152A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| EP4036079B1 (en) | 2015-12-22 | 2025-11-19 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| CN113181106A (zh) | 2016-01-11 | 2021-07-30 | 沃达瑞公司 | 微针组合物及其使用方法 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US20200046830A1 (en) * | 2017-03-30 | 2020-02-13 | The Government Of The United States, As Represented By The Secretary Of The Army | Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines |
| CN110612116A (zh) | 2017-05-08 | 2019-12-24 | 磨石肿瘤生物技术公司 | 甲病毒新抗原载体 |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| ES3028362T3 (en) | 2017-07-24 | 2025-06-19 | Novavax Inc | Methods and compositions for treating respiratory disease |
| IL272281B2 (en) * | 2017-07-28 | 2023-04-01 | Janssen Vaccines Prevention B V | Methods and preparations for heterologous reprna vaccines |
| EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| AU2018331874B2 (en) * | 2017-09-13 | 2022-06-02 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| EP3728291A1 (en) | 2017-12-20 | 2020-10-28 | GlaxoSmithKline Biologicals S.A. | Epstein-barr virus antigen constructs |
| AU2019205330B2 (en) | 2018-01-04 | 2025-09-11 | Iconic Therapeutics Llc | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| SG11202009206QA (en) | 2018-03-19 | 2020-10-29 | Novavax Inc | Multivalent influenza nanoparticle vaccines |
| EP3836963A2 (en) * | 2018-08-17 | 2021-06-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| KR102889984B1 (ko) * | 2019-03-08 | 2025-11-25 | 메사추세츠 인스티튜트 오브 테크놀로지 | 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| MX2021011848A (es) | 2019-03-29 | 2021-10-22 | Intervet Int Bv | Estabilizacion de bacterias mollicutes vivas en una composicion liquida. |
| TW202523847A (zh) | 2019-05-30 | 2025-06-16 | 美商磨石生物公司 | 經修飾之腺病毒 |
| MA56535A (fr) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
| AR120080A1 (es) | 2019-09-19 | 2022-02-02 | Modernatx Inc | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos |
| PH12022551208A1 (en) | 2019-11-18 | 2023-04-24 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| CA3171219A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| EP4126030A1 (en) * | 2020-04-01 | 2023-02-08 | University Of Florida Research Foundation, Incorporated | Multilamellar rna nanoparticle vaccine against sars-cov-2 |
| WO2021229448A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Rna replicon encoding a stabilized corona virus spike protein |
| US20230193311A1 (en) * | 2020-05-20 | 2023-06-22 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| CA3191874A1 (en) | 2020-08-14 | 2022-02-17 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022103927A1 (en) * | 2020-11-12 | 2022-05-19 | Shape Biopharmaceuticals Inc. | Immunogenic compositions for coronaviruses |
| WO2022137128A2 (en) * | 2020-12-23 | 2022-06-30 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| KR20240123832A (ko) | 2021-12-16 | 2024-08-14 | 아퀴타스 테라퓨틱스 인크. | 지질 나노입자 제형에 사용하기 위한 지질 |
| EP4619531A1 (en) | 2022-11-18 | 2025-09-24 | Trustees of Boston University | Self-replicating rna and uses thereof |
| WO2025244961A1 (en) * | 2024-05-22 | 2025-11-27 | Merck Sharp & Dohme Llc | Processes for making stable nanoemulsion adjuvants |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4186745A (en) | 1976-07-30 | 1980-02-05 | Kauzlarich James J | Porous catheters |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| ATE124999T1 (de) | 1985-03-15 | 1995-07-15 | Antivirals Inc | Immunotestmittel für polynukleotid und verfahren. |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| JPH0731857B2 (ja) | 1988-02-19 | 1995-04-10 | 三洋電機株式会社 | 磁気記録再生装置におけるリール台駆動装置 |
| AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US6054288A (en) | 1991-11-05 | 2000-04-25 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| WO1995002597A1 (en) | 1993-07-15 | 1995-01-26 | Minnesota Mining And Manufacturing Company | IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5397307A (en) | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| JP3403233B2 (ja) | 1994-01-20 | 2003-05-06 | テルモ株式会社 | バルーンカテーテル |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
| JPH10509166A (ja) | 1994-11-17 | 1998-09-08 | インペリアル カレッジ オブ サイエンス，テクノロジー アンド メディシン | ポリ−ｌ−リシン及びインテグリンレセプターリガンドの複合体を用いた、ｄｎａのインターナリゼーション |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| ATE225668T1 (de) | 1996-02-12 | 2002-10-15 | Cobra Therapeutics Ltd | Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten |
| DE69841122D1 (de) | 1997-03-10 | 2009-10-15 | Coley Pharm Gmbh | Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6090619A (en) | 1997-09-08 | 2000-07-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
| DE69828963T2 (de) | 1997-10-01 | 2006-01-26 | Medtronic AVE, Inc., Santa Rosa | Wirkstoffabgabe und Gentherapieabgabesystem |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
| HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| DK1126876T3 (da) | 1998-10-16 | 2007-07-02 | Glaxosmithkline Biolog Sa | Adjuvanssystemer og vacciner |
| WO2001021207A2 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| CA2383110A1 (en) | 1999-09-24 | 2001-03-29 | Veronique Henderickx | Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| AU2001290520A1 (en) | 2000-08-01 | 2002-02-13 | The Johns Hokpins University | Intercellular transport protein linked to an antigen as a molecular vaccine |
| JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
| CA2492826C (en) | 2001-09-14 | 2016-12-13 | Cytos Biotechnology Ag | Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
| US20030091593A1 (en) | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| RU2311911C2 (ru) | 2002-07-05 | 2007-12-10 | Липоксен Текнолоджиз Лимитед | Способ усиления иммунного ответа при вакцинации нуклеиновой кислотой |
| ATE471335T1 (de) | 2002-12-23 | 2010-07-15 | Vical Inc | Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden |
| WO2004060308A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
| ATE432285T1 (de) * | 2003-07-11 | 2009-06-15 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| GB2421025A (en) | 2004-12-09 | 2006-06-14 | Oxxon Therapeutics Ltd | HSV vaccination vectors |
| CA2704153A1 (en) | 2007-09-26 | 2009-04-02 | Vanderbilt University | Vaccine for rsv and mpv |
| WO2009074861A2 (en) | 2007-12-10 | 2009-06-18 | Powderject Research Limited | Improved vaccine |
| HUE029258T2 (en) | 2007-12-24 | 2017-02-28 | Id Biomedical Corp Quebec | Recombinant rsv antigens |
| JP5380465B2 (ja) | 2008-03-03 | 2014-01-08 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｔｌｒ活性モジュレーターとしての化合物および組成物 |
| WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
| JP5712126B2 (ja) | 2008-06-25 | 2015-05-07 | ノバルティス アーゲー | 遅延型追加刺激免疫処置に対する迅速な応答 |
| WO2010036948A2 (en) | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| EP4218800A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| CN102665761A (zh) | 2009-11-04 | 2012-09-12 | 玛瑞纳生物技术有限公司 | 活性产生递送分子 |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2556151A1 (en) | 2010-04-07 | 2013-02-13 | Novartis AG | Method for generating a parvovirus b19 virus-like particle |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| WO2012030901A1 (en) * | 2010-08-31 | 2012-03-08 | Novartis Ag | Small liposomes for delivery of immunogen-encoding rna |
| US11730804B1 (en) * | 2022-04-13 | 2023-08-22 | Replicate Bioscience, Inc. | Compositions and methods for the prevention and treatment of rabies virus infection |
-
2012
- 2012-07-06 US US14/130,869 patent/US11058762B2/en active Active
- 2012-07-06 WO PCT/US2012/045854 patent/WO2013006842A2/en not_active Ceased
- 2012-07-06 EP EP12735421.5A patent/EP2729168A2/en not_active Withdrawn
- 2012-07-06 EP EP18209088.6A patent/EP3508219A1/en active Pending
- 2012-07-06 JP JP2014519091A patent/JP2014520807A/ja active Pending
- 2012-07-06 CA CA2841047A patent/CA2841047A1/en not_active Abandoned
-
2016
- 2016-10-27 JP JP2016210783A patent/JP2017025103A/ja active Pending
-
2021
- 2021-05-26 US US17/330,826 patent/US20210290755A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520807A5 (cg-RX-API-DMAC7.html) | ||
| JP2014522842A5 (cg-RX-API-DMAC7.html) | ||
| Foged | Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems | |
| JP2015522580A5 (cg-RX-API-DMAC7.html) | ||
| Cui et al. | Topical immunization using nanoengineered genetic vaccines | |
| Malyala et al. | Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles | |
| Jabbal-Gill | Nasal vaccine innovation | |
| García et al. | An overview of adjuvant formulations and delivery systems | |
| van Riet et al. | Combatting infectious diseases; nanotechnology as a platform for rational vaccine design | |
| Uddin et al. | Overview and future potential of fast dissolving buccal films as drug delivery system for vaccines | |
| Huang et al. | Research progress on emulsion vaccine adjuvants | |
| Kersten et al. | Antigen delivery systems | |
| Shahiwala et al. | Nanocarriers for systemic and mucosal vaccine delivery | |
| Zurbriggen | Immunostimulating reconstituted influenza virosomes | |
| Noh et al. | Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity. | |
| Yadav et al. | Nanovaccines formulation and applications-a review | |
| CN101616687B (zh) | 非特异性免疫刺激剂 | |
| Goetz et al. | Vaccine adjuvants for infectious disease in the clinic | |
| Beg et al. | Colloidal drug delivery systems in vaccine delivery | |
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| von Hoegen | Synthetic biomimetic supra molecular Biovector™(SMBV™) particles for nasal vaccine delivery | |
| US20200054571A1 (en) | Formulation for protection through controlled release of microparticles containing recombinant outer membrane vesicles | |
| Zeng et al. | In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives | |
| Amirnasr et al. | Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46 | |
| CN117298264A (zh) | 基于流感病毒ha蛋白和新冠病毒s蛋白的组合物和疫苗 |